Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Bonnen Lab, |
RCV000149898 | SCV000148965 | pathogenic | Gamma-aminobutyric acid transaminase deficiency | 2014-01-01 | criteria provided, single submitter | research | clinical and in vitro studies |
Elsea Laboratory, |
RCV000149898 | SCV000920599 | pathogenic | Gamma-aminobutyric acid transaminase deficiency | 2019-02-01 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000149898 | SCV004291895 | likely pathogenic | Gamma-aminobutyric acid transaminase deficiency | 2023-10-03 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 211 of the ABAT protein (p.Leu211Phe). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with GABA-transaminase deficiency (PMID: 25738457, 27903293, 29302074). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 162034). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ABAT protein function. Experimental studies have shown that this missense change affects ABAT function (PMID: 25738457, 27903293). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |